Literature DB >> 16644295

Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature.

Hongcheng Liu1, Georgeen Gaza-Bulseco, Joanne Sun.   

Abstract

The susceptible degradation sites of therapeutic proteins are routinely assessed under accelerated conditions such as exposure to chemicals or incubation at elevated temperature or a combination of both. A fully human monoclonal IgG(1) antibody was characterized after incubation at 40 degrees C for 6 months by employing mass spectrometry and chromatography analyses. It was found that deamidation, fragmentation and N-terminal glutamate cyclization to form pyroglutamate are the major degradation pathways. Three major deamidation sites were identified and one site in a small tryptic peptide accounted for more than 80% of the total. Peptide cleavage was observed at several positions between different pairs of amino acids. Most of the cleavage sites were located in the hinge or other flexible regions of the IgG molecule.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644295     DOI: 10.1016/j.jchromb.2006.03.053

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  27 in total

Review 1.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 2.  Silk-based stabilization of biomacromolecules.

Authors:  Adrian B Li; Jonathan A Kluge; Nicholas A Guziewicz; Fiorenzo G Omenetto; David L Kaplan
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

3.  N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies.

Authors:  Y Diana Liu; Andrew M Goetze; Randal B Bass; Gregory C Flynn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

Review 4.  Fragmentation of monoclonal antibodies.

Authors:  Josef Vlasak; Roxana Ionescu
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

5.  Chemical modifications in therapeutic protein aggregates generated under different stress conditions.

Authors:  Quanzhou Luo; Marisa K Joubert; Riki Stevenson; Randal R Ketchem; Linda O Narhi; Jette Wypych
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 6.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

7.  Uncommon Peptide Bond Cleavage of Glucagon from a Specific Vendor under near Neutral to Basic Conditions.

Authors:  Hong-Jian Zheng; Bin-Bin Shen; Jing Wang; Haibin Wang; Guo-Li Huo; Li-Rui Huang; Jian-Qing Gao; Wei-Jie Fang
Journal:  Pharm Res       Date:  2019-06-03       Impact factor: 4.200

Review 8.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

9.  Integrated proteomic analysis of major isoaspartyl-containing proteins in the urine of wild type and protein L-isoaspartate O-methyltransferase-deficient mice.

Authors:  Shujia Dai; Wenqin Ni; Alexander N Patananan; Steven G Clarke; Barry L Karger; Zhaohui Sunny Zhou
Journal:  Anal Chem       Date:  2013-02-06       Impact factor: 6.986

Review 10.  The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies.

Authors:  Tomislav Laptoš; Jasna Omersel
Journal:  Exp Ther Med       Date:  2018-01-31       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.